Todays Times30 Jun 2022 08:49
Shares in biopharmaceuticals firm Avacta swept 9p, or 9 per cent, higher to 109p as it confirmed the first human trials of its chemotherapy drug, AVA6000. Pro-doxorubicin, will advance to its third dose cohort after a “positive review of the safety data” from the second cohort.